Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 19, 2009 Brian Orelli	Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
IndustryWeek February 1, 2007 Jill Jusko	Bookshelf: Opening Up According to a new book, a firm's business model itself has to become more open for the firm to open up its innovation process effectively.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
IndustryWeek November 1, 2008 Jill Jusko	Bookshelf: Closing the Innovation Gap: Reigniting the Spark of Creativity in a Global Economy Judy Estrin's new book addresses a topic that has raised much consternation in the U.S. manufacturing community: the loss of emphasis on innovation in this country, a loss the author attributes in large part to short-term Wall Street thinking as well as an increasing fear of risk-taking.
The Motley Fool October 7, 2008 Brian Orelli	Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
IndustryWeek May 1, 2008 Jill Jusko	Bookshelf: Innovation to the Core: A Blueprint for Transforming the Way your Company Innovates In their new book, Peter Skarzynski and Rowan Gibson detail how to evaluate new growth opportunities, provide guidelines to manage innovation resources and suggest design rules to improve a corporation's innovation pipeline.
IndustryWeek April 15, 2009 Jill Jusko	Ideas Welcomed Add Campbell Soup to consumer products firms inviting innovation via the Web.
IndustryWeek November 18, 2009 Jill Jusko	Improve Your Innovation Pipeline External collaboration and improved portfolio management are among the strategies for success.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
Bio-IT World January 13, 2003 Mark D. Uehling	Prescription for Success: Mix IT and Science Blending IT and R&D: At Eli Lilly, scientists define the "what," IT decides the "how." In the post-genomic era, "Collaboration will be absolutely critical," says CIO Roy Dunbar.
CRM June 24, 2011 Elisa O'Donnell	Kill the Office of Innovation What it really takes to create a thriving innovation capacity within an organization.
HBS Working Knowledge March 20, 2006 Huston & Sakkab	P&G's New Innovation Model Procter & Gamble's assessment of its aging innovation process and the development of connect and develop.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool October 8, 2008 Brian Orelli	Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Rebuttal Shareholders who buy into Lilly at its current valuation just won't have the same opportunity for stock price appreciation as those who bought shares in the late '80s or early '90s.
Entrepreneur January 2004 Nichole L. Torres	It's History How the spirit of innovation has shaped the nation
CIO August 29, 2011 Weiss & Drewry	How Collaboration Enables Affordable Innovation Top companies are turning to crowd sourcing on public and private networks to pave the way to more affordable idea creation.
The Motley Fool March 14, 2011 Brian Orelli	This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business.
IndustryWeek January 1, 2007 Jill Jusko	Consumer Products Companies Best Practices -- A Team Effort Consumer products companies embrace collaboration to speed innovation and product development efforts.
IndustryWeek August 1, 2008 John Teresko	Bookshelf: The Innovator's Guide To Growth: Putting Disruptive Innovation To Work In this new book, the authors take the subject of innovation to the next level -- implementation.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
The Motley Fool August 10, 2010 Amanda B. Kish	Will Hewlett-Packard Burn You? What HP's troubles could mean for some mutual funds, and what investors can do in response.
ifeminists December 28, 2005 Tony Zizza	If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs.
The Motley Fool October 22, 2009 Brian Orelli	Beat Earnings, Stock Down, Rinse and Repeat For the second quarter in a row, Eli Lilly beat expectations, it raised guidance, and its stock fell for the day.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool January 13, 2011 Brian Orelli	FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache.
The Motley Fool April 19, 2004 Alyce Lomax	Eli Lilly's Drug Dependency Competitive concerns make Cymbalta and new drugs more important than ever.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool November 25, 2011	A Brief History of Eli Lilly's Returns The good news is that, with shares now trading at around 10 times earnings, Eli Lilly looks reasonably valued, if not cheap.
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool January 30, 2008 Brian Lawler	Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
The Motley Fool January 26, 2005 Stephen D. Simpson	Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through.
CIO October 15, 2002 Stephanie Overby	They Want a New Drug In the race to develop new pharmaceuticals more quickly, companies are introducing new IT tools. But the tools can't do it alone. CIOs need to change the way people do their work.
Pharmaceutical Executive November 1, 2008 Joanna Breitstein	Gilding Lilly With new CEO John Lechleiter in charge, can Lilly find its way back from the edge?
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
The Motley Fool July 26, 2007 Brian Lawler	Lilly Doesn't Wilt The second quarter was another good one for Eli Lilly. Top-line and bottom-line both grew.
The Motley Fool July 22, 2011 Matt Koppenheffer	Could Eli Lilly's Stock Double Your Money? With concerns swirling around the big pharma companies, could it be time to buy Eli Lilly?
The Motley Fool March 18, 2011 Brian Orelli	Forget Getting Approved, for Now The FDA wants more information on Eli Lilly's Amyvid.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.
The Motley Fool April 19, 2011 Brian Orelli	See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff?